We successfully represented Janssen in this patent infringement action under the new PMNOC Regulations concerning Janssen’s Invega Sustenna (paliperidone palmitate) product used to treat schizophrenia. Following a two week trial, Justice Manson agreed that Teva’s paliperidone palmitate product would directly infringe certain of the patent claims. Teva’s argument that the claimed subject-matter was obvious was rejected.